Incyte Corporation or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?

Managing SG&A Costs: Incyte vs. CRISPR Therapeutics

In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and operational efficiency. Over the past decade, Incyte Corporation and CRISPR Therapeutics AG have demonstrated contrasting approaches to SG&A cost management.

From 2014 to 2023, Incyte Corporation's SG&A expenses have surged by approximately 600%, peaking in 2023. This reflects a strategic investment in administrative capabilities and market expansion. In contrast, CRISPR Therapeutics AG has shown a more conservative increase of around 1,400% over the same period, indicating a rapid scaling phase.

While Incyte's expenses are significantly higher, their growth rate is more stable compared to CRISPR's aggressive expansion. This data provides a fascinating insight into how these biotech giants balance growth with cost management, offering valuable lessons for investors and industry analysts alike.